Psoriasis Treatment Market Market Analysis

In the past few years, the psoriasis treatment landscape in the Middle East and Africa has shifted from predominantly episodic, symptom‑focused care toward more structured chronic disease management, driven by tangible developments in clinical practice, regulatory engagement, and healthcare planning. In Saudi Arabia, reforms linked to the National Health Transformation Program under Vision 2030 expanded access to specialist dermatology services, enabling broader use of systemic therapies in tertiary centers in Riyadh and Jeddah. This pivot was reinforced by educational focus at major scientific gatherings such as the Dubai World Dermatology Conference, where in 2025 there was a strong emphasis on mechanism‑based therapies, signaling a shift in clinician familiarity and adoption. Across North Africa, major referral hospitals in Cairo and Casablanca have strengthened psoriasis care pathways, integrating standardized severity assessments such as PASI scoring into routine practice, contributing to improved consistency in treatment decisions. In sub‑Saharan Africa, outpatient dermatology capacity in Johannesburg and Lagos improved significantly after investment in workforce training and clinic expansion, reducing previously long wait times and enabling earlier intervention with systemic agents. Concurrently, regional research published in 2024 highlighted persistent gaps in patient awareness about disease chronicity and treatment expectations, prompting new physician‑patient educational efforts and community engagement initiatives. National health authorities in the UAE and Morocco have also begun embedding psoriasis within broader non‑communicable disease strategies, recognizing its psychosocial burden. These shifts demonstrate how recent history in the Middle East and Africa is redefining psoriasis care from fragmented symptom relief toward comprehensive, long‑term management frameworks supported by evidence and system reforms. According to the research report, "Middle East and Africa Psoriasis Treatment Market Research Report, 2031," published by Actual Market Research, the Middle East and Africa Psoriasis Treatment market is anticipated to add USD 450 Million by 2026–31.Recently, the competitive and regulatory framework for psoriasis treatment in the Middle East and Africa has matured, marked by accelerated approvals, growing clinical evidence generation, and deeper engagement from multinational therapy developers, reshaping how treatments are positioned and delivered. Regulatory agencies in the United Arab Emirates and Saudi Arabia have streamlined review pathways for advanced biologics and targeted systemic therapies, enabling earlier access in markets once reliant mainly on topical and traditional systemic agents.

Hospitals in Abu Dhabi and Riyadh now routinely include these advanced therapies in chronic care protocols, reflecting a shift in treatment sequencing and long‑term disease control strategies. The region’s growing involvement in global clinical trials has been notable, with leading centers in South Africa and the UAE participating in late‑phase studies of interleukin inhibitors and novel systemic agents, generating region‑specific real‑world evidence that strengthens clinician confidence in biologics and targeted therapies. Major pharmaceutical innovators including AbbVie, Amgen, Johnson & Johnson, Novartis, Eli Lilly, and Pfizer have expanded their presence through robust medical affairs, local partnerships, and education programs that support knowledge dissemination and differentiated therapy adoption. In markets such as Egypt and Nigeria, improvements in supply chains and distribution networks have enhanced the availability of PDE4 inhibitors and biologic classes previously limited to high‑income settings, shifting usage patterns among dermatologists. .

Market Dynamic

Psoriasis Treatment MarketSegmentation

Plaque psoriasis is the most common type in the Middle East and Africa due to its high prevalence and well-documented clinical characteristics.

Plaque psoriasis dominates the Middle East and Africa psoriasis treatment market primarily because of its wide prevalence and the straightforward nature of its clinical presentation. In countries such as Saudi Arabia, Egypt, and South Africa, studies have shown that plaque psoriasis accounts for a large proportion of diagnosed psoriasis cases, often identified through visual inspection and commonly presenting with symptoms like well-defined red, scaly patches on the skin. This type of psoriasis is easily recognizable, making diagnosis more efficient in both rural and urban healthcare settings, contributing to its prominence in the treatment landscape. Furthermore, the disease is less complicated than other forms like pustular or erythrodermic psoriasis, which require more specialized interventions, thus leading to plaque psoriasis being the most treated and discussed in dermatological clinics across the region. The higher incidence and visibility of this type of psoriasis mean that healthcare systems are more equipped with the protocols and treatment regimens specifically targeting plaque psoriasis. These treatments include topical corticosteroids, vitamin D analogs, and increasingly, biologic therapies as awareness of the disease’s chronic nature spreads. Local and regional health organizations, such as the UAE Dermatology Society and the South African Psoriasis Society, have emphasized awareness programs for plaque psoriasis, further reinforcing its prominence. As the primary condition addressed by most dermatologists, plaque psoriasis receives consistent attention in both private and public healthcare settings, ensuring its continued importance in market discussions and shaping treatment approaches across the region.

Interleukin inhibitors are the fastest-growing drug class in the Middle East and Africa due to their high efficacy and favorable safety profile in moderate to severe psoriasis cases.

Interleukin inhibitors, particularly IL-17 and IL-23 inhibitors, have rapidly gained traction in the Middle East and Africa due to their targeted mechanisms of action and exceptional results for patients with moderate to severe psoriasis. These biologics work by blocking the specific interleukins responsible for the inflammatory cascade that leads to skin cell proliferation and the characteristic lesions of psoriasis. In countries like Saudi Arabia and South Africa, where there is an increasing prevalence of moderate to severe psoriasis, interleukin inhibitors offer an alternative to traditional treatments, which may not always provide sufficient relief. The remarkable efficacy of these drugs in clearing plaques and improving the overall quality of life for patients has led to swift adoption by dermatologists in both public and private healthcare sectors. Furthermore, they have demonstrated a better safety profile compared to older systemic treatments, minimizing side effects such as immunosuppression and liver toxicity, making them a preferred choice for long-term management. As a result, many leading healthcare institutions in the region, including those in the UAE and Egypt, have incorporated IL-17 and IL-23 inhibitors into their treatment protocols, driving their increasing use. Additionally, regional healthcare policies and expanding insurance coverage in countries like Saudi Arabia have made these high-cost treatments more accessible, contributing to their rising market presence. Their strong clinical outcomes, improved safety, and better patient satisfaction are central to why interleukin inhibitors are emerging as the fastest-growing drug class in the region.

Biologic drugs dominate the treatment landscape due to their superior efficacy, particularly in severe cases of psoriasis, and growing availability in the region.

Biologic drugs have become the largest treatment category for psoriasis in the Middle East and Africa, driven by their ability to offer unparalleled efficacy in managing moderate to severe forms of the disease. Unlike traditional treatments that focus primarily on symptom management, biologics target the underlying immune system dysfunction that causes psoriasis. Medications like TNF-alpha inhibitors, IL-17, and IL-23 inhibitors are particularly effective in treating patients with extensive plaque or pustular psoriasis, as they can provide near-complete clearance of lesions. In the Middle East, countries such as the UAE and Saudi Arabia have seen an increasing shift towards biologic therapies, especially as access to these treatments improves with government health initiatives and expanding insurance coverage. In South Africa, where the burden of moderate to severe psoriasis is significant, biologic treatments have become the go-to solution for those who fail conventional therapies. This shift has led to biologics becoming central to dermatologists’ treatment regimens across both private and public healthcare systems. Their increasing availability in the region—combined with the introduction of biosimilars that offer cost-effective alternatives—has further reinforced their dominant position. The widespread use of biologics is also supported by a growing body of evidence demonstrating their long-term safety and effectiveness in controlling disease progression and reducing flare-ups, making them the preferred option for both physicians and patients. This marked shift in treatment strategies has cemented biologics as the largest treatment type in the Middle East and Africa psoriasis market.

Oral treatments are the fastest-growing mode of administration in the Middle East and Africa due to their convenience and ease of use for patients.

Oral treatments for psoriasis have gained rapid popularity in the Middle East and Africa due to their convenience and non-invasive nature, which is especially appealing to patients who prefer an easier treatment regimen. Oral systemic therapies such as methotrexate, acitretin, and newer drugs like apremilast offer a simple, at-home treatment option compared to injectables and infusions, which often require visits to medical facilities. In regions with growing access to healthcare infrastructure, including countries like the UAE and South Africa, patients have increasingly favored oral therapies due to their convenience and reduced need for healthcare appointments. This shift aligns with the busy lifestyles of many patients in urban areas, who prefer treatments that do not require frequent hospital visits. Furthermore, oral medications are often perceived as more affordable and less intimidating compared to biologics, which are typically administered via injections or intravenous infusions. As healthcare access improves across the region, especially in rural areas of Africa, the accessibility and affordability of oral treatments allow them to reach a larger patient base. The growing familiarity with oral medications and the simplicity of their administration have contributed to their rising use, making oral therapies the fastest-growing mode of administration in the Middle East and Africa psoriasis treatment market.

Retail pharmacies dominate distribution channels due to their broad accessibility, high patient traffic, and growing self-medication trends in the region.

Retail pharmacies have become the largest distribution channel for psoriasis treatments in the Middle East and Africa due to their widespread presence and accessibility. In countries like Egypt, South Africa, and the UAE, retail pharmacies are often the first point of contact for patients seeking treatment for psoriasis, especially for those with mild to moderate cases who can manage their condition with over-the-counter topical treatments. As the availability of prescription therapies, including biologics and oral treatments, has increased in these pharmacies, they have become a preferred distribution point for both prescription and non-prescription products. The convenience of obtaining medications from neighborhood pharmacies, especially in urban areas, has contributed to their dominance. Furthermore, in many parts of the Middle East and Africa, retail pharmacies are integrating telehealth services, allowing patients to consult pharmacists remotely for treatment advice and medication orders, expanding their role in the treatment continuum. As self-medication trends rise, with patients increasingly seeking to manage their psoriasis at home, retail pharmacies are positioned to fulfill this demand. This accessibility, coupled with the convenience of dispensing medications directly to patients, has solidified retail pharmacies as a major distribution channel in the region’s psoriasis treatment market.

Psoriasis Treatment Market Market Regional Insights

Saudi Arabia leads the Middle East and Africa Psoriasis Treatment Market due to its robust healthcare infrastructure, progressive policies, and increased access to advanced treatments.

Saudi Arabia has emerged as a leader in the Middle East and Africa psoriasis treatment market, owing to its rapidly advancing healthcare systems, strategic investments in dermatology services, and progressive health policies. The Saudi government has significantly increased funding for healthcare through its Vision 2030 initiative, ensuring enhanced access to specialized treatments, including biologics and systemic therapies. This has allowed dermatologists in major cities like Riyadh and Jeddah to offer cutting-edge psoriasis treatments, attracting both regional and international pharmaceutical companies. Furthermore, Saudi Arabia has become a hub for clinical trials, contributing significantly to the region's growing clinical research base. By incorporating international treatment protocols and supporting the introduction of innovative biologics, such as those from AbbVie and Janssen, Saudi Arabia has played a critical role in shaping the treatment landscape across the Middle East and North Africa. Additionally, the country's extensive healthcare networks and increased availability of psoriasis management programs ensure that patients, particularly those with moderate to severe forms of the disease, have access to timely and effective care. s a result of these efforts, Saudi Arabia not only leads in the treatment of psoriasis but also serves as a model for other countries in the region in terms of healthcare investment and patient access to advanced therapies.